

## CORPORATE ACTION INSTRUCTIONS FOR BIOGEN (BIIB) SPIN-OFF OF BIOVERATIV (BIVV)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) today announced that it has been advised by NASDAQ that the common stock for Bioverativ, the spinoff of its global hemophilia business, begins trading today, Thursday, January 12, 2017, on a "when-issued" basis under the symbol "BIVVV" on the NASDAQ Global Select Market. The "when-issued" status of trading of Bioverativ common stock is expected to convert to regular-way trading on Thursday, February 2, 2017, at which time Bioverativ common stock will trade under the symbol "BIVV" on the NASDAQ Global Select Market.



### Warning

Corporate action instructions are provided as a courtesy to our clients to assist with accurate handling of performance calculations in our software. We may provide cost basis information when it is publicly available, but we do not guarantee accuracy or alignment with your custodian. For cost basis and tax reporting, you must rely on your custodian for accurate data. For more information on cost basis reporting, click [here](#).



### Online

For more information regarding this action, please see:

[Corporate Action Information](#)

## SPIN-OFF WIZARD DETAILS

The table below contains the details you need to enter into the PortfolioCenter® Spin-Off Wizard.



### Tip

1. Block any Pending, Warning, or Error interface transactions related to the corporate action before running the Spin-Off Wizard. For more information, see [Identifying Corporate Action Transactions in Interface Data](#).
2. Run the Spin-Off Wizard using the details below. For more information, see [Entering a Spin-Off Corporate Action Transaction](#).

FIELD NAME	DATA FOR THIS ACTIVITY
Spin-Off Date	02/02/2017
Security Type	Equity
Parent Company Symbol	BIIB
Parent Company Price Per Share	\$281.69
New Company Security Type	Equity
New Company Symbol	BIVV
Percent of Cost Allocated	0.00 (Unknown)

<b>FIELD NAME</b>	<b>DATA FOR THIS ACTIVITY</b>
Allocate Value the Same as Cost Basis	Unchecked
New Company Price per Share	\$44.79
Share Distribution Ratio	0.5
Conversion Price for Cash in Lieu For Fractional Shares	\$0.00 (Unknown)



### Tip

After posting the Transaction Writer list, the shares may be unreconciled due to Cash in Lieu of fractional shares that have not been processed by the custodian. Most custodians send these transactions between one day and two weeks after the initial corporate action; they can be identified by the Notes field, which usually includes the abbreviation CIL as well as the symbol. To properly account for Cash in Lieu, edit the custodial transaction and make the following changes:

1. Change the Security Type to the proper type for the security involved, usually Equities
2. Change the activity to Sell.
3. Change the Symbol to the security symbol.
4. Enter the fractional share quantity, which can be found on the Share Reconciliation report.
5. Change the matching method to First In First Out.
6. Post the sell transaction.

After performing these steps, both shares and cash should reconcile.

For institutional audiences only.

© 2017 Schwab Performance Technologies® (“SPT”). All rights reserved

PortfolioCenter® and PortfolioCenter Hosted™ are products of Schwab Performance Technologies® (“SPT”). SPT is a subsidiary of The Charles Schwab Corporation separate from its affiliate Charles Schwab & Co., Inc. (“CS&Co”). CS&Co is a registered broker-dealer and member SIPC that provides brokerage services, while SPT licenses software and provides related technology products and services. SPT and CS&Co are separate companies affiliated as subsidiaries of The Charles Schwab Corporation, but their products and services are independent from each other. SPT’s intelligent integration solutions integrate data about accounts custodied at CS&Co.

The information contained in this document is furnished to users of SPT products as an accommodation and without charge. While efforts have been made to provide accurate information, SPT does not guarantee its accuracy, timeliness, or completeness. Nor do we warrant or guarantee any results from your use of or reliance on the information. Your receipt of this information is subject to the [Terms and Conditions](#) of the SPT website at [schwab.com/public/spt/nn/terms.html](http://schwab.com/public/spt/nn/terms.html). For definitive information, we urge you to consult the official documents and information available from the issuers of the securities that are the subjects of the transactions described.

This document is not intended to provide tax or legal advice about the transactions described. Users are urged to consult their tax advisors and legal counsel about the tax consequences and their legal rights of the transactions.